Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Howdy Phantom, You said "No reason this shouldn't be fully enrolled right now." I would hope that is correct. The Very Slow enrollment has been my concern for a long time. Which is why in Nov. 2023 I emailed Juan Vera and asked/suggested "As most Doctors know about CAR-T but not Multi-TAA, if we want to raise awareness with Doctors about Marker and their Multi-TAA therapy and it's advantages over CAR-T therapy, have you considered spending some money to advertise with some large size ads in the most prestigious medical journals like JAMA (Journal of the American Medical Association), The New England Journal of Medicine, Journal of Clinical Oncology? So that they can treat more patients and have quicker enrollment progress which hopefully would lead to a larger amount of positive result data?"
In Jan 2024 I posted a fear here "I think one problem MRKR has all along for any trials is awareness. If Doctors and patients don't know about your company or trials, it's hard to sign them up for it. I hate to say this ... but ... how much of this slow recruiting for trials has to do with both Hospital competition and greed. In other words if MRKR contacts M.D. Anderson or Mayo Clinic and says: "we have this therapy for patients "X", you might want to enroll them in our trial. Will those Hospitals and Doctors recommend that their patients go elsewhere for treatment because they would both no longer be able to charge the Insurance companies for any treatments that they themselves would have given and billed for?? I would hope not, but people are people."
As far as enrollment and data, I whole heartedly agree with you "they better not disappoint", the BS lame excuses got old a long time ago.
That would be nice, but I ain't holding by breathe.
I have owned this stock for about a quarter of a century back to when it was Tapimmune TPIV, that is more than 1/3 of my life. It is and has been one of my largest investments, my average cost is mid teens and needless to say, it has not performed very well. Back at under $3 again, I would like to say:
HELPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPP
Low $3's again. GEEZ.
I think it may be illegal for potential partners to be given data that has not been released yet. Wouldn't that be inside information?
MRKR needs a lot more trial success proof before a partner would step up.
"The data showed that three out of three participants had objective responses" ... the word "objective", is very objective.
"expect to provide an update on safety and durability during the third quarter." ... that would be nice.
MT-601 (Pancreatic) "Clinical advancement will be pending additional financial support from non-dilutive funding activities." ... OK, I guess.
"Marker had cash and cash equivalents of $7.8 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the fourth quarter of 2025, inclusive of available drawdowns from grant funds." ...
... at least that's good.
"G&A Expenses: General and administrative expenses were $1.1 million for the quarter ended June 30, 2024, compared to $2.5 million for the quarter ended June 30, 2023." ... OK I guess.
"Net Loss: Marker reported a net loss from continuing operations of $2.2 million for the quarter ended June 30, 2024, compared to $4.1 million for the quarter ended June 30, 2023." ... OK I guess.
I guess back to waiting and hoping.
Honestly, No I do not. That's a better question for Phantom than for me. Sorry.
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-reports-second-quarter-2024-financial
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-awarded-2-million-grant-nih-support-phase-1
Oh OK, Thank You, I did read that. I'm getting old and got a bit confused, I thought it was something new and he was saying that some secondary part of an FDA trial was ending for some reason.
I feel better, I was think oh no, not another trial ending.
Thank You Again.
I am getting whiplash from all this up and down and up and down and back and forth.
Please elaborate, what cancel the secondary? is this recent news? I have read nothing recently.
I am glad at your first line of the $ lost isn’t affecting your lifestyle as I retired 14 years ago and am in that same boat. I am sad at your B/E point of $100. I, now in hindsight was an idiot and just kept buying to average down so many times I lost count. The good is you lower your average, the bad is you wind up investing four times as much as you really normally would have. At this point, I just pretend it is all lost, or that it was all a donation to try to cure cancer, no different than my giving to St. Judes Childrens Hospital, other than that, not much to do except wait and hope.
Thank You, I'm just doing the wait and hope game. It kind of looks like someone has been accumulating for the last couple of month, but the low volume stinks, need accumulation with huge volume, guess we just have to wait for some good news. I would like to know about How Many Lymphoma patients they are treating. Seems like we both, and others, spent a good chunk of our lives typing on this board.
price slowly going up ... great
volume ... SUCKS
Phantom ... have you heard any new news?
Message to whoever has been buying the dips for the last couple of weeks, slowly raising the share price.
KEEP DOING THAT.
Thank You
Hello, triple digits may be hard, if everything goes perfect for a few more years, then maybe, sorry, just trying to be somewhat rational.
Great news might bring $20+ in a short time , above $50 would need a TON of revenue I would think.
Now, can we keep climbing? Hope so.
ARE WE ALL RICH YET?
Phantom, Thank You for contacting JV and filling us in. Your timeline for event seems the most reasonable.
I think our main problem is, Nobody has heard of MRKR, Doctors, Patients, Investors.
I have not and will not sell a single share, but I kind of give up trying to figure this price.
3 patients, 2 great news and 1 good news, AND IT DOES BASICALLY NOTHING ???
Have a great summer.
Thank You
I think so but not positive. It may just be a rehash of what they just gave us.
Cash looks OK also:
Cash Position and Guidance: At March 31, 2024, Marker had cash and cash equivalents of $11.3 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the fourth quarter of 2025, inclusive of available drawdowns from grant funds.
It all sounds good so far, 3 patients, 3 for 3 good results.
First study participant treated with MT-601 had diffuse large B cell lymphoma (DLBCL) and failed four prior lines of therapy, including a relapse within 90 days of anti-CD19 CAR T cell therapy (Breyanzi) (PRESS RELEASE, JUNE 12, 2023). Without prior lymphodepletion, this participant achieved a complete response eight weeks after the second infusion of MT-601 and remains in complete response nine months after initial treatment with MT-601 (PRESS RELEASE, APRIL 8, 2024).
Another study participant had transformed follicular Non-Hodgkin’s Lymphoma (NHL) and failed 12 lines of therapy, including bispecific T cell engager therapy (mosunetuzumab) for follicular NHL, and anti-CD19 CAR T cells (Yescarta) after transformation into DLBCL. At the time of MT-601 infusion, only follicular NHL persisted in this patient. Eight weeks after initial infusion with MT-601 without prior lymphodepletion, the study participant achieved a complete response, which remains three months following treatment with MT-601(PRESS RELEASE, APRIL 8, 2024).
The third study participant treated had DLBCL with cutaneous involvement and was not eligible for CAR T cell therapy. This participant achieved a partial response eight weeks after MT-601 treatment without prior lymphodepletion with all lesions decreasing in size including one that has completely resolved (PRESS RELEASE, APRIL 8, 2024).
Treatment was well tolerated among all patients with no significant treatment-related adverse events including cytokine release syndrome or neurotoxicity.
Thank You. sounds good ... for now.
Thank You. Hope something comes out of MT-401 OTS.
I'm guessing that this no new nothing news means that there ain't going to be any earth shattering news given by Juan at tomorrows presentation.
YAWN!
Ho Hum, it looks like the same Old information being told again for the 10th time.
Thanks for the update on lymphoma patient #1 again, again.
MARKER THERAPEUTICS REPORTS YEAR-END 2023 CORPORATE AND FINANCIAL RESULTS
https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-reports-year-end-2023-corporate-and
Hello Phantom, asking in advance. After Juan does his March 26 presentation, can you translate it here and give your outlook? Thank You
volume 17,000 , that's not a lot of excitment.
Nice move, but the pitiful volume Sucks.
Ho Hum. go mrkr. rah rah rah.
should start tomorrow.
Lymphoma patient #2? Lymphoma patient #3? We can expect some data when?
Well, we can look at the bright side. At least we have the name "Neldaleucel" ready ... in case we ever get to use it to market ...
in 3 or 4 years if we're lucky.
GO METS you see we have out own "Acuna" now.
OK, let me get this straight.
It has been more than 20 years since TPIV came public,
about 6 years since the MRKR merger,
and what we have to show for it is basically nothing.
All TPIV legacy gone bye bye.
MRKR AML just about gone bye bye.
And here we are, back to almost square one, with a single early Phase 1 Lymphoma trial.
Just Peachy.